Immunovant, Inc. (IMVT) Fair Value 2026

IMVT · Biological Products, (No Diagnostic Substances) ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.0 /10

32 fundamental signals · 10 models active

Value Trap Risk

— (—/100)

Quick Summary — As of 2026-07-15, Immunovant, Inc. (IMVT) trades at $39.88, approximately 175% above CirclFi’s Bayesian DCF fair value of $14.48. QOC: 5.0/10. 10/13 models active.

Key Facts

Ticker
IMVT
Price
$39.88
Quality Score
5.0/10
Value Trap Risk
—/100
Models Active
10/13
Last Updated
Strength: First Chicago suggests +42.9% upside with 16% confidence
Risk: Majority of models suggest overvaluation

Is Immunovant, Inc. (IMVT) Undervalued or Overvalued in 2026?

According to CirclFi’s 10-model valuation engine, Immunovant, Inc. (IMVT) appears overvalued as of : the median of 10 independent fair value estimates is $15.74, 60.5% below the current price of $39.88. Estimates range from $1.40 to $56.99. IMVT scores 5.0/10 on fundamental quality and —/100 on value-trap risk.

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Immunovant, Inc. Stock in 2026? →

Valuation Matrix

10 Intrinsic Value Models vs. Current Price ($39.88)

Core Models (Unlocked)
Model Fair Value Upside
Bayesian DCF
Low Conviction
 $14.48 -63.7%
Earnings Power Value
High Conviction
 $17.01 -57.4%
CUCE Ensemble
Low Conviction
 $19.38 -51.4%
First Chicago
Low Conviction
 $56.99 +42.9%

Unlock the Full Matrix

Access 6 additional models including EROIC Spread, Markov DDM, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 10 Models →

Cancel anytime · No contracts · Instant access

What Is Immunovant, Inc. (IMVT) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Immunovant, Inc.'s intrinsic value is estimated at a composite fair value of $22.60. Trading at $39.88, the stock is approaching fair value or slight overvaluation (implied return of -43.3%), as 7 of 10 models suggest limited further upside. Model dispersion is worth noting: First Chicago targets $56.99 (+42.9%), versus ML-RIV at $1.40 (-96.5%). This +139.4% range highlights the importance of multi-model analysis rather than relying on any single methodology.

What Do the Models Say About IMVT?

10 of 13 models are currently active for IMVT. Of these, 2 models suggest upside while 8 models suggest overvaluation. The Bayesian DCF estimates IMVT's intrinsic value at $14.48, implying -63.7% downside from the current price. See which stocks rank higher →

How Does IMVT Rank in Biological Products, (No Diagnostic Substances)?

Among 134 Biological Products, (No Diagnostic Substances) stocks, IMVT ranks #74 by Quality of Company score. CirclFi's QOC score of 5.0/10 evaluates 32 fundamental signals. A score of 5.0 reflects mixed fundamentals.

See all Most Undervalued Biological Products, (No Diagnostic Substances) Stocks →

Immunovant, Inc. operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.

Is IMVT a Value Trap?

The Value Trap algorithm is not active for IMVT. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

10 of 13 models are active for Immunovant, Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, Immunovant, Inc. scores 5.0 out of 10 on our 32-signal quality assessment, a moderate rating that shows mixed signals across our quality framework with notable weaknesses. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

The gap between the most bullish and bearish model spans +139.4% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every IMVT valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across IMVT's 10 active models, average confidence is 35%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Immunovant, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biological Products, (No Diagnostic Substances) Stocks Should You Also Analyze?

8 related Biological Products, (No Diagnostic Substances) stocks with 13-model coverage

EXELExelixis, Inc.QOC 10.0HALOHalozyme Therapeutics, Inc.QOC 10.0NBIXNeurocrine Biosciences, Inc.QOC 10.0GILDGilead Sciences, Inc.QOC 9.7PLXProtalix BioTherapeutics, Inc. QOC 8.6BIIBBiogen Inc.QOC 8.4IMCRImmunocore Holdings plcQOC 7.9TECHBio-Techne CorpQOC 7.8

Read investment analysis: EXEL · HALO · NBIX · GILD · PLX

See all Biological Products, (No Diagnostic Substances) stocks ranked →

Frequently Asked Questions About Immunovant, Inc.

What is Immunovant, Inc.'s intrinsic value in 2026?

Based on CirclFi's 13-model analysis, Immunovant, Inc. (IMVT) has multiple fair value estimates. The Bayesian DCF model runs 10,000 Monte Carlo simulations with jump-diffusion to estimate intrinsic value at $14.48. The Quality of Company score is 5.0/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is IMVT overvalued or undervalued right now?

At $39.88, 2 of 10 active models suggest IMVT may be undervalued, while 8 indicate potential overvaluation. The median of all 10 fair value estimates is $15.74, 60.5% below the current price of $39.88 — a consensus view that IMVT is overvalued. The assessment depends on which methodology best fits Immunovant, Inc.'s business model in Biological Products, (No Diagnostic Substances).

What does a Quality of Company score of 5.0 mean for IMVT?

Immunovant, Inc.'s QOC of 5.0/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on IMVT?

CirclFi analyzes IMVT with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 10 of 13 are active for this stock. Read the full methodology →

Is IMVT a value trap in 2026?

CirclFi's Value Trap algorithm does not have sufficient data for IMVT at this time. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 10-model valuation engine, Immunovant, Inc. (IMVT) has a median fair value of $15.74 — 60.5% below the current price of $39.88 — as of 2026-07-15.” Source: circlfi.com/stock/IMVT/ · Methodology

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 10 mathematical frameworks give you clarity on IMVT.

Unlock All 10 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access